Thrombosis News and Research

Latest Thrombosis News and Research

BioInvent, ThromboGenics initiate TB-402 Phase IIb trial for VTE prophylaxis

ThromboGenics NV and co-development partner BioInvent International announce today that the first patient has been dosed in a Phase IIb trial with their novel long-acting anticoagulant TB-402 for the prophylaxis of venous thromboembolism after total hip surgery.

27 Apr 2011

Too much TV raises risk of narrow eye blood vessels and heart disease in kids

A new study has shown that children who spend more time in front of television and computer screens and less in outdoor physical activity have narrower blood vessels in their eyes. In adults, constricted blood vessels in the eyes have been linked to an increased risk of cardiovascular disease.

26 Apr 2011

Experts to present research on vascular biology and disease at ATVB meetings

Nearly 1,200 experts in cardiovascular medicine, vascular biology, endocrinology, hematology and other disciplines are expected to attend the American Heart Association's Arteriosclerosis, Thrombosis and Vascular Biology 2011 Scientific Sessions, April 28-30, in Chicago, Ill.

26 Apr 2011

Rwanda, QIAGEN and Merck launch comprehensive national cervical cancer prevention program

The Government of Rwanda, together with QIAGEN N.V. and Merck, known as MSD outside the United States and Canada, today announced the launch, in Kigali, Rwanda, of a comprehensive national cervical cancer prevention program that includes vaccination with GARDASIL [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant] for appropriate girls 12 to 15 years of age and modern molecular diagnostic screening for women between the ages of 35 and 45.

From QIAGEN Manchester Limited 25 Apr 2011

Bayer's oral contraceptives may increase risk of blood clots, stroke or heart attack

Bayer HealthCare Pharmaceuticals, Inc. is aware of two studies published today in The British Medical Journal, ONLINE FIRST.

25 Apr 2011

Daiichi Sankyo's LIXIANA receives Japanese marketing approval

Daiichi Sankyo Company, Limited, announced today that the company has received its first marketing approval for LIXIANA 15 mg and 30 mg tablets, by the Ministry of Health, Labor and Welfare in Japan.

22 Apr 2011

Sedentary lifestyle in childhood narrows vessels in the retina and increases risk of cardiovascular disease

Six-year-olds who spent the most time watching television, using a computer or playing video games had narrower arteries in the back of their eyes — a marker of future cardiovascular risk, in a first-of-its-kind study reported in Arteriosclerosis, Thrombosis and Vascular Biology: Journal of the American Heart Association.

21 Apr 2011

Cumberland acquires Vanderbilt's ifetroban rights

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company focused on hospital acute care and gastroenterology markets, today announced that it has entered into an agreement to acquire the rights to ifetroban, a new Phase II development product.

19 Apr 2011

GRAVITAS study shows no benefit of double-dose compared with standard-dose clopidogrel

An international consortium of scientists, including major contributions from the Montreal Heart Institute, demonstrates that the "one-size fits all" strategy of uniformly doubling the dose of an antiplatelet drug, clopidogrel, for patients with high on-treatment platelet reactivity does not reduce the incidence on death, heart attacks and stent thrombosis after percutaneous coronary intervention.

16 Apr 2011

Cytonet initiates clinical trial using liver cell infusion to treat urea cycle disorders in children

International biotechnology firm Cytonet recently launched the first ever clinical trial in the United States using an investigational liver cell infusion to treat urea cycle disorders (UCD) in children. The first patient in the Phase II trial, which will seek to enroll 20 patients in 12 medical centers, is a child with citrullinemia, which is a hereditary UCD. He received six liver cell infusions on six consecutive days at Yale School of Medicine in New Haven, Conn.

15 Apr 2011

Scientists identify cellular switch that may help treat cardiovascular disease, cancer

Scientists at the University of Hull have identified a cellular 'on-off' switch that may have implications for treating cardiovascular disease and cancer.

7 Apr 2011

J&JPRD announces rivaroxaban Phase 3 trial results against venous thromboembolism

Johnson & Johnson Pharmaceutical Research & Development, L.L.C., today announced results from the MAGELLAN Phase 3 trial evaluating the investigational oral anticoagulant rivaroxaban for the prevention of venous thromboembolism in hospitalized patients with acute medical illnesses.

6 Apr 2011

Positive outcomes from Medtronic's Resolute drug-eluting stent against coronary artery disease

Results of two major clinical studies presented at ACC.11 - the 60th Annual Scientific Session & Expo of the American College of Cardiology - demonstrate that the Resolute drug-eluting stent from Medtronic, Inc., provides a positive and persistent treatment effect for a wide variety of patients with coronary artery disease.

5 Apr 2011

Abbott's XIENCE V Coronary Stent System data presented at ACC meeting

A pooled analysis of the SPIRIT II, III, IV and COMPARE trials presented today further reinforces the positive clinical performance of Abbott's market-leading XIENCE V Everolimus Eluting Coronary Stent System.

4 Apr 2011

Positive results from Abbott's ABSORB device trial in coronary artery disease

Abbott today announced positive one-year results from 101 patients enrolled in the second phase of the ABSORB trial evaluating the world's first drug eluting Bioresorbable Vascular Scaffold for the treatment of coronary artery disease.

4 Apr 2011

Regado's REG1 system Phase 2b trial results presented at i2 Summit

Regado Biosciences, Inc., a privately held company pioneering the development of antithrombotic aptamers with active control agents, announced today the primary results of the RADAR Phase 2b clinical trial of the company's lead product, the anticoagulation system REG1, at the i2 Summit during the American College of Cardiology 2011 60th Annual Scientific Session & Expo in New Orleans, LA.

4 Apr 2011

Merck's VICTRELIS phase III study results against HCV presented at EASL annual meeting

Merck, known as MSD outside of the United States and Canada, announced results from several new data analyses from the pivotal Phase III studies evaluating the addition of its investigational oral protease inhibitor VICTRELIS to peginterferon alfa-2b and ribavirin in adult patients with chronic hepatitis C virus genotype 1 infection.

1 Apr 2011

Texas Children's Hospital and Baylor College of Medicine create Texas Children's Center for Global Health

Texas Children's Hospital and Baylor College of Medicine (BCM) today announced the creation of the Texas Children's Center for Global Health and the appointment of renowned physician-scientist Dr. Russell E. Ware as director.

31 Mar 2011

ACCF, AHA guidelines recognize Effient as Class I treatment option for patients with ACS-PCI

Oral antiplatelet therapy Effient has been added to the updated clinical practice guidelines as a Class I recommended treatment option for patients undergoing percutaneous coronary intervention fter experiencing heart-related chest pain at rest or non-ST segment elevation myocardial infarction.

30 Mar 2011

Regado to present REG1 Phase 2b trial results against acute coronary syndromes at i2 Summit

Regado Biosciences, Inc., a privately held company pioneering the development of antithrombotic aptamers with active control agents, announced that Thomas J. Povsic, MD, PhD, Assistant Professor of Medicine at Duke University, will present results of the RADAR Phase 2b clinical trial for the Company's lead product, the REG1 anticoagulation system, at the i2 Summit during the American College of Cardiology 2011 60th Annual Scientific Session & Expo.

29 Mar 2011

Thrombosis News and Research

Latest Thrombosis News and Research

BioInvent, ThromboGenics initiate TB-402 Phase IIb trial for VTE prophylaxis

Too much TV raises risk of narrow eye blood vessels and heart disease in kids

Experts to present research on vascular biology and disease at ATVB meetings

Rwanda, QIAGEN and Merck launch comprehensive national cervical cancer prevention program

Bayer's oral contraceptives may increase risk of blood clots, stroke or heart attack

Daiichi Sankyo's LIXIANA receives Japanese marketing approval

Sedentary lifestyle in childhood narrows vessels in the retina and increases risk of cardiovascular disease

Cumberland acquires Vanderbilt's ifetroban rights

GRAVITAS study shows no benefit of double-dose compared with standard-dose clopidogrel

Cytonet initiates clinical trial using liver cell infusion to treat urea cycle disorders in children

Scientists identify cellular switch that may help treat cardiovascular disease, cancer

J&JPRD announces rivaroxaban Phase 3 trial results against venous thromboembolism

Positive outcomes from Medtronic's Resolute drug-eluting stent against coronary artery disease

Abbott's XIENCE V Coronary Stent System data presented at ACC meeting

Positive results from Abbott's ABSORB device trial in coronary artery disease

Regado's REG1 system Phase 2b trial results presented at i2 Summit

Merck's VICTRELIS phase III study results against HCV presented at EASL annual meeting

Texas Children's Hospital and Baylor College of Medicine create Texas Children's Center for Global Health

ACCF, AHA guidelines recognize Effient as Class I treatment option for patients with ACS-PCI

Regado to present REG1 Phase 2b trial results against acute coronary syndromes at i2 Summit

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Thrombosis News and Research

Latest Thrombosis News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in